Amgen’s Blincyto gains EU approval for consolidation phase treatment in B-ALL

Amgen has received European Commission approval for Blincyto (blinatumomab) as part of consolidation therapy in adults with newly diagnosed Philadelphia chromosome-negative CD19-positive B-cell precursor acute ... Read More